| Literature DB >> 26690215 |
Sihan Song1, Eunkyung Hwang2, Hyeong-Gon Moon3,4, Dong-Young Noh5,6, Jung Eun Lee7.
Abstract
There is limited evidence on the association between adherence to guidelines for cancer survivors and health-related quality of life (HRQoL). In a cross-sectional study of Korean breast cancer survivors, we examined whether adherence to the guidelines of the American Cancer Society (ACS) and World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) for cancer survivors was related to levels of HRQoL, assessed by the Korean version of Core 30 (C30) and Breast cancer module 23 (BR23) of the European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ). We included a total of 160 women aged 21 to 79 years who had been diagnosed with breast cancer according to American Joint Committee on Cancer (AJCC) stages I to III and had breast cancer surgery at least six months before the interview. Increasing adherence to ACS guidelines was associated with higher scores of social functioning (p for trend = 0.05), whereas increasing adherence to WCRF/AICR recommendations was associated with higher scores of arm symptoms (p for trend = 0.01). These associations were limited to those with stage II or III cancer. Diet may be an important factor in relation to quality of life among Korean breast cancer survivors, however our findings warrant further prospective studies to evaluate whether healthy diet improves survivors' quality of life.Entities:
Keywords: breast cancer survivors; cancer survivor guidelines; health-related quality of life
Mesh:
Year: 2015 PMID: 26690215 PMCID: PMC4690084 DOI: 10.3390/nu7125532
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Operationalization of adherence to ACS guidelines.
| ACS Guidelines for Cancer Survivors | Sub-Guidelines | Operationalization | Scoring | |
|---|---|---|---|---|
Achieve and maintain a healthy weight. | If overweight or obese, limit consumption of high-calorie foods and beverages and increase physical activity to promote weight loss. | BMI (kg/m2) | ||
| 18.5–22.9 | 2 | |||
| 23-25 | 1 | |||
| <18.5 or >25 | 0 | |||
Engage in regular physical activity. | Avoid inactivity and return to normal daily activities as soon as possible following diagnosis. Aim to exercise at least 150 min per week. Include strength training exercises at least 2 days per week. | METs (h/week) | ||
| Tertile 3 (>40.3) | 2 | |||
| Tertile 2 (19.6–43.3) | 1 | |||
| Tertile 1 (<19.6) | 0 | |||
Achieve a dietary pattern that is high in vegetables, fruits, and whole grains. | Eat 5 or more servings of a variety of vegetables and fruits each day. | Fruits and vegetables intake (g/day) | ||
| Tertile 3 (>659.2) | 2 | Tertiles High 2 Middle 1 Low 0 | ||
| Tertile 2 (443.1–659.2) | 1 | |||
| Tertile 1 (<443.1) | 0 | |||
Choose whole grains in preference to processed (refined) grains. | Percentage of grains consumed as whole grains (%) | |||
| Tertile 3 (90–100) | 2 | |||
| Tertile 2 (64.3–90) | 1 | |||
| Tertile 1 (0–64.3) | 0 | |||
Limit consumption of processed and red meats. | Red and processed meat intake (g/day) | |||
| Tertile 1 (<5) | 2 | |||
| Tertile 2 (5–60.7) | 1 | |||
| Tertile 3 (>60.7) | 0 | |||
Abbreviations: ACS, American Cancer Society; BMI, Body Mass Index; MET, metabolic equivalent task.
Operationalization of adherence to WCRF/AICR recommendations.
| WCRF/AICR Recommendations for Cancer Survivors | Sub-Recommendations | Operationalization | Scoring | |
|---|---|---|---|---|
Body fatness: Be as lean as possible without becoming underweight | Ensure that body weight throughout childhood and adolescent growth projects toward the lower end of the normal BMI range at age 21 years Maintain body weight within the normal range from age 21 years Avoid weight gain and increases in waist circumference throughout adulthood | BMI (kg/m2) | ||
| 18.5–22.9 | 2 | |||
| 23-25 | 1 | |||
| <18.5 or >25 | 0 | |||
Physical activity: Be physically active as part of your everyday life | Be moderately physically active, equivalent to brisk walking, for ≥30 min every day As fitness improves, aim for ≥60 min of moderate, or for ≥30 min of vigorous physical activity every day Limit sedentary habits such as watching television | Physical activity (MET-hour/week) | ||
| Tertile 3 (>40.3) | 2 | |||
| Tertile 2 (19.6–43.3) | 1 | |||
| Tertile 1 (<19.6) | 0 | |||
Foods and drinks that promote weight gain: Limit consumption of energy-dense foods; avoid sugary drinks | Consume energy-dense foods (225–275 kcal/100 g) sparingly Avoid sugary drinks (servings/week) Consume fast foods sparingly, if at all | Energy dense diet 1 (kcal/100 g) | Tertiles High 2 Middle 1 Low 0 | |
| Tertile 1 (<154.2) | 2 | |||
| Tertile 2 (132–154.2) | 1 | |||
| Tertile 3 (>132) | 0 | |||
| Sugary drinks (g/day) | ||||
| None | 2 | |||
| ≤50 | 1 | |||
| >50 | 0 | |||
Plant foods: Eat mostly foods of plant origin | Eat ≥5 portions/servings (>400 g) of a variety of non-starchy vegetables and of fruits every day Eat relatively unprocessed cereals (grains) and/or pulses (legumes) with every meal Limit refined starchy foods People who consume starchy roots or tubers as staples should also ensure sufficient intake of non-starchy vegetables, fruit, and pulses (legumes) | Non-starchy vegetable and fruit intake (g/day) | Tertiles High 2 Middle 1 Low 0 | |
| Tertile 3 (>586.2) | 2 | |||
| Tertile 2 (371.5–586.2) | 1 | |||
| Tertile 1 (<371.5) | 0 | |||
| Refined grains (g/day) | ||||
| Tertile 1 (<15) | 2 | |||
| Tertile 2 (15–45) | 1 | |||
| Tertile 3 (>45) | 0 | |||
Animal foods: Limit intake of red meat (beef, pork, lamb, and goat) and avoid processed meat | People who eat red meat should consume <500 g/week, very little if any to be processed meats | Red meat and processed meat intake (g/day) | ||
| Tertile 1 (<5) | 2 | |||
| Tertile 2 (5–60.5) | 1 | |||
| Tertile 3 (>60.5) | 0 | |||
Preservation, processing, preparation: Limit consumption of salt. Avoid moldy cereals (grains) or pulses (legumes) | Avoid salt-preserved, salted, or salty foods; preserve foods without using salt Limit consumption of processed foods with added salt to ensure an intake of<6 g (2.4 g sodium)/day Do not eat moldy cereals (grains) or pulses (legumes) | Sodium intake (mg/day) | ||
| Tertile 1 (<3521.7) | 2 | |||
| Tertile 2 (3521.7–4602.2) | 1 | |||
| Tertile 3 (>4602.2) | 0 | |||
Abbreviations: WCRF/AICR, World Cancer Research Fund/American Institute for Cancer Research; BMI, Body Mass Index; MET, metabolic equivalent task; 1 Energy dense diet denotes energy intake per amount of total food intake (kcal per 100 g).
Characteristics of study participants according to adherence score of ACS or WCRF/AICR guidelines.
| ACS Guidelines Score | WCRF/AICR Recommendation Score | ||||
|---|---|---|---|---|---|
| Characteristic | All ( | Q1 ( | Q4 ( | Q1 ( | Q4 ( |
| Age, mea | 50.96 ± 8.72 | 51.78 ± 6.84 | 52.75 ± 8.45 | 50.50 ± 9.09 | 50.76 ± 8.54 |
| Body mass index, mea | 22.58 ± 2.84 | 24.19 ± 3.57 | 21.25 ± 1.39 | 24.36 ± 3.44 | 21.41 ± 1.50 |
| Physical activity, mea | 37.88 ± 37.78 | 16.19 ± 22.74 | 58.07 ± 40.16 | 15.26 ± 11.59 | 52.56 ± 34.67 |
| Educatio | |||||
| High school or below | 90 (56.25) | 25 (50.00) | 29 (60.42) | 20 (50.00) | 17 (51.52) |
| College or above | 68 (42.50) | 25 (50.00) | 18 (37.50) | 20 (50.00) | 15 (45.45) |
| Marital status, | |||||
| Married or cohabitation | 135 (84.38) | 41 (82.00) | 40 (83.33) | 30 (75.00) | 29 (87.88) |
| Unmarried or divorced or widowed | 24 (15.00) | 9 (18.00) | 8 (16.67) | 10 (25.00) | 4 (12.12) |
| Current menopausal status, | |||||
| Premenopausal | 16 (10.00) | 5 (10.00) | 1 (2.08) | 5 (12.50) | 3 (9.09) |
| Postmenopausal | 137 (85.63) | 43 (86.00) | 44 (91.67) | 35 (87.50) | 29 (87.88) |
| Time since surgery, | |||||
| 6 month–<1 year | 26 (16.25) | 8 (16.00) | 8 (16.67) | 7 (17.50) | 3 (9.09) |
| 1 year–<2 years | 65 (40.63) | 17 (34.00) | 24 (50.00) | 15 (37.50) | 18 (54.55) |
| 2 years–<5 years | 43 (26.88) | 14 (28.00) | 11 (22.92) | 9 (22.50) | 8 (24.24) |
| ≥5 years | 26 (16.25) | 11 (22.00) | 5 (10.42) | 9 (22.50) | 4 (12.12) |
| AJCC stage at diagnosis, | |||||
| I | 73 (45.63) | 21 (42.00) | 24 (50.00) | 20 (50.00) | 16 (48.48) |
| II | 70 (43.75) | 22 (44.00) | 19 (39.58) | 14 (35.00) | 15 (45.45) |
| III | 17 (10.63) | 7 (14.00) | 5 (10.42) | 6 (15.00) | 2 (6.06) |
| Estroge | |||||
| Negative | 49 (30.63) | 14 (28.00) | 17 (35.42) | 8 (20.00) | 12 (36.36) |
| Positive | 108 (67.50) | 34 (68.00) | 30 (62.50) | 31 (77.50) | 21 (63.64) |
| Progesterone receptor status, | |||||
| Negative | 70 (43.75) | 19 (38.00) | 21 (43.75) | 17 (42.50) | 16 (48.48) |
| Positive | 87 (54.38) | 29 (58.00) | 26 (54.17) | 22 (55.00) | 17 (51.52) |
| Energy intake, mea | 1749.59 ± 380.37 | 1676.96 ± 319.93 | 1871.90 ± 413.24 | 1779.77 ± 375.23 | 1796.31 ± 435.29 |
| Dietary supplement use, | |||||
| No | 56 (35.00) | 17 (34.00) | 12 (25.00) | 17 (42.50) | 8 (24.24) |
| Yes | 104 (65.00) | 33 (66.00) | 36 (75.00) | 23 (57.50) | 25 (75.76) |
| Alcohol intake, | |||||
| Never drinker | 76 (47.50) | 28 (56.00) | 24 (50.00) | 19 (47.50) | 15 (45.45) |
| Ever drinker | 83 (51.88) | 22 (44.00) | 23 (47.92) | 21 (52.50) | 18 (54.55) |
| Smoking status, | |||||
| Never smoker | 139 (86.88) | 45 (90.00) | 36 (75.00) | 36 (90.00) | 26 (78.79) |
| Ever smoker | 5 (3.13) | 1 (2.00) | 2 (4.17) | 2 (5.00) | 1 (3.03) |
Abbreviations: ACS, American Cancer Society; WCRF/AICR, World Cancer Research Fund/American Institute for Cancer Research; SD, standard deviation; MET, metabolic equivalent task; AJCC, American Joint Committee on Cancer; 1 Number of participants was less than 160 because some participants did not provide relevant information.
Health-related quality of life (HRQoL) scores according to ACS guidelines adherence score among breast cancer survivors with stage I to III (n = 160) 1.
| ACS Guidelines Score | ||||||
|---|---|---|---|---|---|---|
| HRQOL Items | Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| ACS score, range | 160 | 0–2 | 3 | 4 | 5–6 | |
| EORTC QLQ-C30, LS means (95% CI) | ||||||
| Global health status/QoL | 134 | 23.36 (15.32–35.62) | 30.73 (18.74–50.39) | 33.10 (19.08–57.44) | 25.19 (16.00–39.67) | 0.68 |
| Functioning | ||||||
| Physical Functioning | 158 | 75.67 (65.17–87.87) | 77.87 (65.48–92.59) | 83.99 (69.25–101.86) | 76.60 (65.13–90.09) | 0.74 |
| Role Functioning | 160 | 63.64 (48.26–83.92) | 79.45 (56.88–110.98) | 105.76 (72.86–153.52) | 81.32 (59.63–110.89) | 0.07 |
| Emotional Functioning | 160 | 71.80 (58.30–88.43) | 73.83 (57.41–94.96) | 60.06 (45.36–79.51) | 79.72 (63.11–100.70) | 0.67 |
| Cognitive Functioning | 160 | 72.15 (61.40–84.79) | 71.48 (58.82–86.86) | 88.74 (71.40–110.29) | 66.52 (55.51–79.72) | 0.77 |
| Social Functioning | 160 | 57.16 (46.21–70.69) | 64.57 (49.95–83.48) | 77.86 (58.47–103.67) | 71.06 (55.99–90.19) | 0.05 |
| Symptom | ||||||
| Fatigue | 159 | 27.30 (20.25–36.79) | 25.76 (18.12–36.62) | 19.77 (13.35–29.28) | 24.65 (17.74–34.24) | 0.37 |
| Nausea and vomiting | 160 | 2.71 (1.59–4.62) | 2.93 (1.54–5.57) | 2.35 (1.15–4.82) | 2.60 (1.43–4.73) | 0.79 |
| Pain | 159 | 10.26 (5.74–18.35) | 15.99 (8.06–31.72) | 6.79 (3.16–14.59) | 8.38 (4.42–15.89) | 0.28 |
| Dyspnea | 158 | 4.84 (2.53–9.24) | 4.53 (2.11–9.71) | 4.20 (1.80–9.84) | 3.32 (1.63–6.78) | 0.32 |
| Insomnia | 158 | 12.66 (6.94–23.09) | 17.57 (8.65–35.69) | 18.25 (8.27–40.28) | 21.30 (10.95–41.44) | 0.14 |
| Loss of appetite | 158 | 2.48 (1.34–4.59) | 2.27 (1.10–4.68) | 3.08 (1.37–6.93) | 1.89 (0.96–3.73) | 0.59 |
| Constipation | 158 | 6.92 (3.62–13.21) | 5.00 (2.34–10.65) | 6.96 (2.99–16.20) | 6.48 (3.19–13.14) | 0.99 |
| Diarrhea | 160 | 3.83 (2.14–6.84) | 2.73 (1.35–5.50) | 2.76 (1.26–6.03) | 2.93 (1.53–5.62) | 0.45 |
| Financial impact | 160 | 9.73 (5.17–18.29) | 7.18 (3.35–15.40) | 9.18 (3.92–21.49) | 5.70 (2.81–11.57) | 0.22 |
| EORTC QLQ-BR23, LS means (95% CI) | ||||||
| Functioning | ||||||
| Body image | 160 | 42.54 (27.15–66.64) | 32.57 (18.94–56.01) | 48.20 (26.33–88.24) | 29.92 (18.08–49.50) | 0.35 |
| Sexual functioning | 153 | 1.91 (1.03–3.55) | 2.70 (1.28–5.67) | 2.36 (1.05–5.30) | 4.01 (2.00–8.03) | 0.06 |
| Future perspective | 160 | 36.99 (21.71–63.02) | 27.65 (14.53–52.64) | 43.67 (21.30–89.53) | 32.90 (18.10–59.82) | 0.95 |
| Symptom | ||||||
| Systematic therapy side effects | 160 | 21.95 (16.30–29.55) | 25.72 (17.95–36.84) | 19.12 (12.80–28.54) | 18.89 (13.53–26.36) | 0.26 |
| Breast symptoms | 160 | 14.19 (8.71–23.11) | 12.32 (6.83–22.21) | 10.31 (5.35–19.89) | 11.08 (6.41–19.14) | 0.34 |
| Arm symptoms | 160 | 19.25 (12.92–28.68) | 25.87 (15.99–41.87) | 20.03 (11.71–34.26) | 28.65 (18.32–44.79) | 0.17 |
| Upset by hair loss | 101 | 23.78 (11.61–48.74) | 19.30 (8.45–44.07) | 18.83 (6.41–55.36) | 42.87 (18.83–97.59) | 0.20 |
Abbreviations: ACS, American Cancer Society; LS means, least-squares means; 95% CI, 95% confidence interval; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; BR23, breast cancer module 23; 1 Models were adjusted for age (year; continuous), energy intake (kcal/day; continuous), dietary supplement use (yes, no), education level (high school or below, college or above), marital status (married or cohabitation, unmarried or divorced or widowed), breast cancer stage (I, II, III), and time since surgery (6 month-1, 1–5, ≥5 years); 2 p for trend was calculated using the median value of each quartile category as a continuous variable.
Health-related quality of life (HRQoL) scores according to WCRF/AICR recommendation adherence score among breast cancer survivors with stage I to III (n = 160) 1.
| WCRF/AICR Recommendation Score | ||||||
|---|---|---|---|---|---|---|
| HRQOL Items | Q1 ( | Q2 ( | Q3 ( | Q4 ( | ||
| WCRF/AICR score, range | 160 | 1–4 | 5–6 | 7–8 | 9–12 | |
| EORTC QLQ-C30, LS means (95% CI) | ||||||
| Global health status/QoL | 134 | 28.10 (18.45–42.79) | 24.41 (14.76–40.38) | 24.46 (15.37–38.92) | 30.15 (17.70–51.35) | 0.90 |
| Functioning | ||||||
| Physical Functioning | 158 | 76.29 (65.68–88.62) | 82.08 (69.05–97.58) | 78.00 (66.15–91.98) | 73.95 (61.33–89.16) | 0.63 |
| Role Functioning | 160 | 68.05 (50.95–90.89) | 84.26 (60.64–117.08) | 77.20 (56.02–106.39) | 84.76 (58.87–122.05) | 0.44 |
| Emotional Functioning | 160 | 70.61 (57.00–87.47) | 80.71 (63.27–102.94) | 75.44 (59.50–95.63) | 62.86 (48.00–82.32) | 0.41 |
| Cognitive Functioning | 160 | 70.72 (59.80–83.63) | 77.45 (64.01–93.71) | 74.37 (61.76–89.56) | 64.81 (52.46–80.05) | 0.46 |
| Social Functioning | 160 | 54.17 (43.64–67.25) | 77.34 (60.49–98.89) | 68.10 (53.59–86.54) | 76.71 (58.42–100.73) | 0.09 |
| Symptom | ||||||
| Fatigue | 159 | 24.81 (18.36–33.52) | 22.30 (15.67–31.74) | 27.73 (19.81–38.80) | 25.92 (17.69–37.97) | 0.45 |
| Nausea and vomiting | 160 | 2.67 (1.55–4.62) | 2.41 (1.29–4.48) | 2.76 (1.51–5.05) | 3.09 (1.55–6.14) | 0.61 |
| Pain | 159 | 11.07 (6.13–19.99) | 8.51 (4.25–17.02) | 11.01 (5.69–21.30) | 8.50 (4.02–18.00) | 0.81 |
| Dyspnea | 158 | 4.86 (2.55–9.29) | 3.62 (1.69–7.73) | 4.63 (2.25–9.54) | 2.65 (1.17–6.03) | 0.39 |
| Insomnia | 158 | 11.98 (6.59–21.78) | 18.84 (9.34–38.00) | 18.97 (9.73–36.99) | 29.80 (13.87–64.04) | 0.05 |
| Loss of appetite | 158 | 2.12 (1.15–3.92) | 2.78 (1.36–5.71) | 2.94 (1.48–5.83) | 1.49 (0.68–3.27) | 0.61 |
| Constipation | 158 | 6.99 (3.67–13.31) | 3.64 (1.72–7.69) | 7.45 (3.65–15.19) | 6.33 (2.82–14.22) | 0.52 |
| Diarrhea | 160 | 4.35 (2.41–7.86) | 2.31 (1.18–4.53) | 2.39 (1.24–4.59) | 3.52 (1.67–7.42) | 0.57 |
| Financial impact | 160 | 9.56 (5.00–18.26) | 5.68 (2.72–11.86) | 8.70 (4.24–17.83) | 5.44 (2.40–12.30) | 0.54 |
| EORTC QLQ-BR23, LS means (95% CI) | ||||||
| Functioning | ||||||
| Body image | 160 | 37.58 (23.91–59.07) | 41.99 (25.12–70.21) | 44.50 (26.96–73.45) | 19.70 (11.15–34.83) | 0.13 |
| Sexual functioning | 153 | 1.74 (0.92–3.27) | 3.57 (1.73–7.37) | 3.86 (1.93–7.71) | 2.23 (1.03–4.84) | 0.42 |
| Future perspective | 160 | 39.37 (22.84–67.85) | 40.48 (21.80–75.15) | 28.91 (15.81–52.86) | 23.83 (12.00–47.31) | 0.10 |
| Symptom | ||||||
| Systematic therapy side effects | 160 | 24.14 (17.78–32.77) | 17.69 (12.50–25.04) | 20.63 (14.70–28.95) | 21.59 (14.69–31.73) | 0.86 |
| Breast symptoms | 160 | 13.62 (8.26–22.47) | 11.63 (6.59–20.55) | 10.44 (6.00–18.18) | 15.16 (8.07–28.48) | 0.99 |
| Arm symptoms | 160 | 18.09 (12.07–27.13) | 22.70 (14.32–35.98) | 27.16 (17.34–42.55) | 35.55 (21.34–59.23) | 0.01 |
| Upset by hair loss | 101 | 24.21 (11.96–48.97) | 11.95 (4.80–29.77) | 29.39 (12.72–67.89) | 39.41 (16.07–96.68) | 0.10 |
Abbreviations: WCRF/AICR, World Cancer Research Fund/American Institute for Cancer Research; LS means, least-squares means; 95% CI, 95% confidence interval; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; BR23, breast cancer module 23; 1 Models were adjusted for age (year; continuous), energy intake (kcal/day; continuous), dietary supplement use (yes, no), education level (high school or below, college or above), marital status (married or cohabitation, unmarried or divorced or widowed), breast cancer stage (I, II, III), and time since surgery (6 month-1, 1–5, ≥5 years); 2 p for trend was calculated using the median value of each quartile category as a continuous variable.